10th Complement-Based Drug Development Summit

Capitalizing on Late-Stage Clinical Success, Strengthening Target & Modality Differentiation & Translating Complement into Ocular, CNS, Oncology & Autoimmune Indications

The 10th Complement-Based Drug Development Summit returns at a pivotal moment as the field shifts from validating complement biology to maximizing its clinical and commercial potential. As pipelines expand beyond C3 and C5 and competition intensifies, developers are focused on identifying the right targets, modalities, and indications to drive differentiation and patient impact.

Recent milestones, including Regeneron's cemdisiran advancing through FDA and EMA review and Biogen's acquisition of Apellis, highlight the growing momentum and investment shaping the next era of complement therapeutics.

As the industry's only dedicated forum uniting complement leaders, this meeting will address the strategic and scientific priorities shaping the next generation of complement therapeutics, including:

- Advancing clinical success through biomarker innovation, improved target engagement strategies, robust trial design, and smarter indication selection to de-risk development

- Benchmarking next-generation modalities across siRNA, gene therapy, biologics, and novel delivery technologies to improve durability, efficacy, safety, and patient outcomes

- Expanding beyond C3 and C5 to evaluate intracellular complement biology, emerging targets, novel mechanisms, and combination approaches shaping the next generation of complement therapeutics

- Unlocking growth beyond renal disease by assessing the translational and clinical opportunity across neurodegenerative, ocular, autoimmune, haematological, oncology, and acute indications